A comprehensive view of sanofi sa. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
Published: April 26, 2024 by Sanofi SA
Sanofi reports 7% year-over-year Q1 sales growth fueled by new launches, with Dupixent sales rising 24.9% YoY to €2,835M; robust performance supports its full-year guidance, despite a drop in business EPS and IFRS EPS
Published: April 25, 2024 by Sanofi SA
Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published: April 23, 2024 by Sanofi SA
Sanofi SA Champions Early Diagnosis and Quality of Life in Rare Diseases and Chronic Conditions, Impacting Over 30 Million in Europe
Published: April 20, 2024 by Industry Intelligence Inc.
Sanofi's frexalimab shows high efficacy in 48-week Phase 2 trial for multiple sclerosis, with an annualized relapse rate of 0.04 for high-dose variants; Phase 3 studies have begun for both relapsing and non-relapsing secondary progressive MS
Published: April 17, 2024 by Sanofi SA

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count